AllAnalyst Report
Morningstar•November 03, 2020
Morningstar•November 03, 2020Bausch Health Companies Inc.: Bausch Reports Improved Q3 With Sales Near Pre-Coronavirus Level; Spin-Off at Least a Year Away
Summary
Formerly known as Valeant Pharmaceuticals, Bausch Health is a global specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the dermatology, gastrointestinal, and ophthalmology markets. The company reports revenue in four segments: Bausch+Lomb and international (55% of revenue), Salix pharmaceuticals (25%), ortho dermatology (6%), and diversified products (14%), and approximately 13% of revenue is attributable to non-
Subscribe to Yahoo Finance Plus Essential for full access
Exclusive reports, detailed company profiles, and best-in-class trade insights to take your portfolio to the next level
Actions
Download Full ReportRelated Reports
- Daily Spotlight: Demand Shifts for U.S. DebtApr 19, 2024 •
BIIB
- Technical Assessment: Neutral in the Intermediate-TermApr 19, 2024 •
AA, LLY
- Analyst Report: Johnson & JohnsonApr 18, 2024 •
JNJ
- Market Update: DFS, JNJ, LVS, TRVApr 18, 2024 •
DFS, JNJ, LVS, TRV
- Analyst Report: Eli Lilly and CompanyApr 17, 2024 •
LLY
Analyst Profile
Aaron Degagne
Equity AnalystAaron DeGagne is an equity analyst, financial services, for Morningstar Research Services LLC, a wholly owned subsidiary of Morningstar, Inc. He contributes primarily to the research coverage of South American banks and Canadian insurance companies and conducts general research on the global financial-services sector.Before joining Morningstar in 2017, DeGagne was an accounting intern for Campgroup and completed two lending-group internships with RBC Capital Markets.DeGagne holds a Bachelor of Business Administration in finance from the University of Notre Dame’s Mendoza College of Business.